Most patients with CLL and melanoma are diagnosed with pathologic Stage III disease or lower, and a literature review has demonstrated that melanoma in patients with CLL has variable incidences of BRAF and NRAS mutations [10]. The gene discussed is NRAS; the disease is B-cell chronic lymphocytic leukemia.